Skip to main content
. 2022 Jan;11(1):87–99. doi: 10.21037/tlcr-21-1033

Figure 3.

Figure 3

Efficacy and survival characteristics of patients with different immunotherapy lines. (A) Objective response rate, (B) progression-free survival, and (C) overall survival in patients with different pembrolizumab treatment lines (n=110). *, P<0.05. PD, progressive disease; SD, stable disease; NR, not reached; PR, partial response.